HyTest

Turku, Finland Founded: 1994 • Age: 32 yrs Acquired By Mindray
Immunological reagents are produced for diagnostic and research applications.

About HyTest

HyTest is a Healthcare company based in Turku (Finland) founded in 1994, and was acquired by Mindray in May 2021. Immunological reagents are produced for diagnostic and research applications. HyTest offers products and services including Monoclonal Antibodies, Antigens, Polyclonal Antibodies, and Sera and Plasma Products. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Proteomics. Its legal entity is HyTest Ltd.

Company details

Founded in 1994 and based in Turku, Finland, HyTest specializes in the development, production, and marketing of immunological reagents, including monoclonal and polyclonal antibodies, sera, plasma, and antigens. These products target areas such as cardiovascular disease, inflammation, infectious diseases, autoimmune diseases, veterinary applications, microbial, and plant toxins. An exclusive agreement has been established with Affinity Life Sciences for assays based on their patented SES-BNP technology to detect proBNP and BNP.

  • Headquarters Turku, Finland
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website hytest.fi/home
  • Social LinkedIn X Facebook YouTube
  • Acquired by Mindray (May 2021)
  • Legal Name Hytest Ltd.
Key Metrics

Products & Services of HyTest

HyTest offers a comprehensive portfolio of products and services, including Monoclonal Antibodies, Antigens, Polyclonal Antibodies, and Sera and Plasma Products.

Monoclonal Antibodies
Diagnostic Reagents

Antibodies used for developing laboratory tests worldwide

Antigens
Diagnostic Reagents

Components for immunoassay and test development applications

Polyclonal Antibodies
Diagnostic Reagents

Antibodies for various clinical assay developments

Sera and Plasma Products
Diagnostic Materials

Products supporting blood-related diagnostic tests

Apps and channels of HyTest

its YouTube channel Hytest Ltd has 110 subscribers and 24 videos.

Hytest Ltd
YouTube 110 subscribers 24 videos Science & Technology
Open channel

Videos from HyTest

The most watched videos on HyTest's YouTube channel, Hytest Ltd (110 subscribers). Click a video to play it here.

NT-proBNP assays and standardization
4.2K views
Audioslides Lp-PLA2 - a Prognostic Marker of Coronary Events
1.8K views
HyTest Webinar Video - COVID 19 Biomarkers to Distinguish Severity and Prognosis
1.4K views
BNP Measurements and Entresto
1K views

More on Hytest Ltd.

Investors in HyTest

HyTest has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Mindray and Summa Equity.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Summa Equity is focused on thematic and impact investments.
2016summaequity.com
Provider of medical equipment & accessories for both human and veterinary
1991mindray.comShenzhen, China
Premium access

Investor details for HyTest

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of HyTest

3 dated milestones of HyTest across 27 years, from founding to its latest funding, stage changes and deals.

  1. Founded HyTest is founded.
  2. Exit Acquired by Summa Equity.
  3. Exit Acquired by Mindray.

Web traffic of HyTest

The website of HyTest (hytest.fi) receives about 8.2K visits a month.

  • Monthly visits
    8.2K

    ▼ 19.8% vs previous month

Similar websites

Websites whose visitors overlap most with HyTest. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
novusbio.com
100%
199.6K#232,152View details
proteinbiosystems.com
proteinbiosystems.com
100%
–
qedbio.com
100%
4.9K#3,910,628View details
rockland-inc.com
100%
View details
micropharm.co.uk
100%
#10,048,263View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 24 similar websites and full traffic analytics for HyTest

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 24 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Hytest

Premium access

Complete news archive for HyTest

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about HyTest

HyTest was founded in 1994.

HyTest is headquartered in Turku, Finland. It is registered at Turku, Varsinais-suomi, Finland.

Founded in 1994 and based in Turku, Finland, HyTest specializes in the development, production, and marketing of immunological reagents, including monoclonal and polyclonal antibodies, sera, plasma, and antigens. These products target areas such as cardiovascular disease, inflammation, infectious diseases, autoimmune diseases, veterinary applications, microbial, and plant toxins. An exclusive agreement has been established with Affinity Life Sciences for assays based on their patented SES-BNP technology to detect proBNP and BNP.

HyTest offers Monoclonal Antibodies, Antigens, Polyclonal Antibodies, and Sera and Plasma Products.

HyTest has 2 investors. Key investors include Mindray, and Summa Equity.

HyTest operates through Hytest Ltd..

Yes. HyTest was acquired by Mindray in May 2021.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available